SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Total Current Liabilities
SCI Pharmtech Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Current Liabilities
NT$960.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Current Liabilities
NT$1.8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-1%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Current Liabilities
NT$689.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Current Liabilities
NT$8.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
18%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Current Liabilities
NT$2.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Total Current Liabilities
NT$52.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Total Current Liabilities?
Total Current Liabilities
960.5m
TWD
Based on the financial report for Sep 30, 2025, SCI Pharmtech Inc's Total Current Liabilities amounts to 960.5m TWD.
What is SCI Pharmtech Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
4%
Over the last year, the Total Current Liabilities growth was 6%. The average annual Total Current Liabilities growth rates for SCI Pharmtech Inc have been 10% over the past three years , 10% over the past five years , and 4% over the past ten years .
